Literature DB >> 8516568

Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas.

R Göke1, B Wagner, H C Fehmann, B Göke.   

Abstract

The glucose-dependent action of GLP-1 (7-36) amide (GLP-1) on insulin secretion was studied in isolated islets and in the perfused rat pancreas. In islet experiments in the presence of non-stimulatory glucose levels (< 3 mmol/l) a GLP-1 concentration of 10 nmol/l increased insulin secretion by 83%. However, higher GLP-1 concentrations (25 and 100 nmol/l) could not further enhance this effect (85 and 83%, respectively). The onset of the stimulatory action of a supramaximal GLP-1-load (25 nmol/l) was at a glucose level of 3 mmol/l. In the perfused pancreas, 25 nmol/l GLP-1 induced a strong insulin release at 5 mmol/l glucose, but under basal glucose (2.8 mmol/l) only a slight enhancement of insulin secretion occurred during the late phase (30 to 54 min) of perfusion (P < 0.05). In conclusion, a slight but not dose-dependent stimulation of insulin secretion by supramaximal GLP-1 loads under basal glucose levels was found. The necessary GLP-1 concentrations to achieve this in vitro effect are beyond physiological or postprandial levels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516568     DOI: 10.1007/BF02576216

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  16 in total

1.  Antidiabetogenic action of truncated glucagon-like peptide-1 in mice.

Authors:  B Ahrén
Journal:  Endocrine       Date:  1995-05       Impact factor: 3.633

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

4.  Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.

Authors:  Jacob D Brown; Danielle McAnally; Jennifer E Ayala; Melissa A Burmeister; Camilo Morfa; Layton Smith; Julio E Ayala
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-06-27       Impact factor: 3.619

Review 5.  A role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion.

Authors:  Makoto Shigeto; Chae Young Cha; Patrik Rorsman; Kohei Kaku
Journal:  J Mol Med (Berl)       Date:  2017-01-17       Impact factor: 4.599

6.  Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice.

Authors:  T Linn; K Schneider; B Göke; K Federlin
Journal:  Acta Diabetol       Date:  1996-03       Impact factor: 4.280

7.  Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: role of PKA-independent mechanisms.

Authors:  J Gromada; S Dissing; P Rorsman
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

8.  Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells.

Authors:  Shi-Ying Ding; Andongfac Nkobena; Catherine A Kraft; Michele L Markwardt; Mark A Rizzo
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

9.  Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

Authors:  C Qualmann; M A Nauck; J J Holst; C Orskov; W Creutzfeldt
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

10.  Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells.

Authors:  H C Fehmann; M Janssen; B Göke
Journal:  Acta Diabetol       Date:  1995-10       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.